
Being the gatekeeper is not the same as being the guide
Europe could play a valuable role: China develops quickly; Europe contributes scientific scrutiny, population diversity and insight into different treatment systems. Together, both regions generate evidence that is globally usable. There is a less flattering possibility. China generates the molecule, conducts the early research, completes the pivotal study and establishes the first market. Europe enters near the end, identifies what is missing and requests supplementary evidence. Europe retains influence over entry, but increasingly little influence over the route used to reach it. Being the gatekeeper is not the same as being the guide. If Europe wants Chinese companies to involve European patients before pivotal decisions are fixed, Europe must offer more than regulatory legitimacy later. Europe has outstanding investigators, early-phase networks, diverse populations and translational expertise. But it also has fragmented processes, slower site activation and higher operating costs. The invitation to bring Phase I trials to Europe must be accompanied by an effort to make Europe worth the diversion.
